Evaluation of the efficacy of nutraceuticals in the adjunct treatment of canine osteoarthritis: a randomized controlled trial

Project Abstract

This randomized controlled trial evaluated the efficacy of select nutraceuticals as adjunctive therapy for canine osteoarthritis (OA) to determine improvements in pain, function, and quality of life beyond standard NSAID treatment. A sample of 120 client-owned dogs with radiographically confirmed OA were enrolled and randomized into three groups in a double-blind design a control group receiving NSAID therapy alone, a low-dose nutraceutical group, and a high-dose nutraceutical group. Nutraceutical formulation included glucosamine sulfate, chondroitin sulfate, methylsulfonylmethane (MSM), and omega-3 fatty acids, standardized for active ingredient content and administered orally for 12 weeks. Primary outcomes were changes in owner-assessed pain and locomotion scores using the Canine Brief Pain Inventory (CBPI) and the Helsinki Chronic Pain Index (HCPI). Secondary outcomes included objective gait analysis metrics, activity monitoring via accelerometry, client satisfaction, and incidence of adverse events. Assessments were conducted at baseline, 4, 8, and 12 weeks, with a follow-up period at 16 weeks to assess durability of effects. Blinded evaluators conducted clinical examinations, and all data analysts were blinded to group allocation. The nutraceutical groups demonstrated statistically significant improvements in CBPI total scores and HCPI scores at weeks 8 and 12 compared with the NSAID-only group (p<0.01 for both primary outcomes). Objective gait analysis revealed increased stride length and decreased stance time variability in the nutraceutical groups, indicating enhanced locomotor function, with greater magnitude in the high-dose group (p<0.05). Accelerometry data showed a higher overall activity index in nutraceutical-treated dogs, correlating with owner-reported improvements (r=0.62, p<0.01). Ulterior outcomes included reductions in rescue analgesic requests and improved owner global impression of change in the high-dose group (p<0.05). Safety profiles were comparable across groups, with no significant hepatic, renal, or hematologic abnormalities attributable to nutraceuticals; mild gastrointestinal symptoms occurred in a minority and were self-limiting. Subgroup analyses suggested amplified benefits in younger senior dogs and those with mild to moderate OA severity at baseline. Multivariate regression identified baseline pain scores and physical activity as significant predictors of response magnitude, while adherence correlated with outcome improvements. The study supports the adjuvant use of standardized nutraceuticals with NSAIDs to enhance pain relief and functional capacity in canine OA, offering a non-pharmacologic option that may reduce NSAID exposure over time. Limitations include a relatively short follow-up for chronic disease progression and potential variability in owner compliance. Further long-term trials are warranted to evaluate disease-modifying potential, optimal dosing strategies, and cost-effectiveness across diverse canine populations.

Project Overview

What This Project Is About

---

A plain-language overview of whether adding nutraceuticals to standard care helps dogs with osteoarthritis feel better and move more easily, compared to standard care alone. Nutraceuticals are supplements with potential anti-inflammatory or joint-supporting effects. The project tests if these supplements provide additional benefits when used alongside conventional treatments in dogs with arthritis.

---

---

The Problem It Addresses

---

Many dogs suffer from osteoarthritis, which causes pain and reduced mobility. While diet, exercise, and medicines help, owners and veterinarians seek safer, accessible options to improve quality of life. This study fills the gap by evaluating whether nutraceuticals offer extra relief beyond standard care and whether they are safe for daily use in dogs.

---

---

Objectives of the Project

---

1. Determine if nutraceuticals improve pain scores in dogs with osteoarthritis when added to standard treatment.
2. Assess changes in mobility and daily activity using simple, owner-friendly scales.
3. Evaluate safety and tolerability by monitoring adverse effects and lab parameters.
4. Compare outcomes between nutraceuticals versus placebo in a controlled setting.

---

---

What You Will Do Step by Step

---

1. Review existing literature on nutraceuticals used for canine osteoarthritis.
2. Design a randomized controlled trial with two groups: nutraceuticals plus standard care vs. placebo plus standard care.
3. Recruit canine participants and obtain owner consent.
4. Administer interventions for a defined period and collect pain and mobility data from owners and clinicians.
5. Monitor safety with routine veterinary checks and blood work as needed.
6. Analyze data using basic statistical comparisons to detect differences between groups.
7. Interpret findings in light of practical relevance for veterinarians and owners.

---

---

Expected Outcome

It is expected that adding nutraceuticals will result in greater improvements in pain relief and mobility with no significant safety concerns, supporting their use as an adjunct to standard care if benefits are demonstrated.